Author | Zach Hartman


Denosumab Most Effective in High-Risk Prostate Cancer Patients

October 02, 2013

The anti-RANKL antibody denosumab is more effective for preventing bone metastasis in men with high-risk castration-resistant prostate cancer compared with low-risk disease, according to results of a new study.

FDG-PET May Help Predict Lung Cancer Survival

September 23, 2013

Analysis of 18F FDG-PET standardized uptake values may be a useful technique for predicting survival in patients with inoperable stage III non–small-cell lung carcinoma, according to a new study.

Night Shifts Implicated in Increased Prostate Cancer Risk

September 05, 2013

Shift work is positively associated with higher levels of prostate-specific antigen (PSA) levels in men between the ages of 40 and 65, according to results of a new study.